Search research articles
Contact Us
Filters
Showing results (1-10 of 75) with videos related to
Page
of 8
Sort By:
Bulletin Du Cancer
|
June 30, 2024
Une nouvelle place pour les biomarqueurs circulants dans le cancer du rein en 2024 ?
Ronan Flippot, Lucia Carril-Ajuria
Drugs
|
September 7, 2018
Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma
Ronan Flippot, Bernard Escudier, Laurence Albiges
Bulletin Du Cancer
|
January 1, 2019
Ronan Flippot, Lisa Derosa, Laurence Albiges
Therapeutic Advances in Medical Oncology
|
March 28, 2020
Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma
Elie Rassy, Ronan Flippot, Laurence Albiges
The Urologic Clinics of North America
|
July 1, 2020
Management of Metastatic Renal Cell Carcinoma with Variant Histologies
Ronan Flippot, Vijay Damarla, Bradley A McGregor
Journal of Oncology Practice
|
May 13, 2016
Therapeutic Strategies for Patients With Metastatic Renal Cell Carcinoma in Whom First-Line Vascular Endothelial Growth Factor Receptor-Directed Therapies Fail
Gabriel G Malouf, Ronan Flippot, David Khayat
Bulletin Du Cancer
|
May 20, 2015
[FGF/FGFR signalling: Implication in oncogenesis and perspectives]
Ronan Flippot, Moumini Kone, Nicolas Magné, et al.
Drugs
|
July 1, 2020
Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma
Laure Hirsch, Ronan Flippot, Bernard Escudier, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
April 4, 2020
On the Shoulders of Giants: The Evolution of Renal Cell Carcinoma Treatment-Cytokines, Targeted Therapy, and Immunotherapy
Janice P Dutcher, Ronan Flippot, Jaleh Fallah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 30, 2018
Non-Clear Cell Renal Cell Carcinomas: From Shadow to Light
Laurence Albiges, Ronan Flippot, Nathalie Rioux-Leclercq, et al.
Page
of 8
Search research articles
Search
Showing results (1-10 of 75) with videos related to
Sort By:
Page
of 8
Bulletin Du Cancer
|
June 30, 2024
Une nouvelle place pour les biomarqueurs circulants dans le cancer du rein en 2024 ?
Ronan Flippot, Lucia Carril-Ajuria
Drugs
|
September 7, 2018
Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma
Ronan Flippot, Bernard Escudier, Laurence Albiges
Bulletin Du Cancer
|
January 1, 2019
Ronan Flippot, Lisa Derosa, Laurence Albiges
Therapeutic Advances in Medical Oncology
|
March 28, 2020
Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma
Elie Rassy, Ronan Flippot, Laurence Albiges
The Urologic Clinics of North America
|
July 1, 2020
Management of Metastatic Renal Cell Carcinoma with Variant Histologies
Ronan Flippot, Vijay Damarla, Bradley A McGregor
Journal of Oncology Practice
|
May 13, 2016
Therapeutic Strategies for Patients With Metastatic Renal Cell Carcinoma in Whom First-Line Vascular Endothelial Growth Factor Receptor-Directed Therapies Fail
Gabriel G Malouf, Ronan Flippot, David Khayat
Bulletin Du Cancer
|
May 20, 2015
[FGF/FGFR signalling: Implication in oncogenesis and perspectives]
Ronan Flippot, Moumini Kone, Nicolas Magné, et al.
Drugs
|
July 1, 2020
Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma
Laure Hirsch, Ronan Flippot, Bernard Escudier, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
April 4, 2020
On the Shoulders of Giants: The Evolution of Renal Cell Carcinoma Treatment-Cytokines, Targeted Therapy, and Immunotherapy
Janice P Dutcher, Ronan Flippot, Jaleh Fallah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 30, 2018
Non-Clear Cell Renal Cell Carcinomas: From Shadow to Light
Laurence Albiges, Ronan Flippot, Nathalie Rioux-Leclercq, et al.
Page
of 8